Alendronate has been shown to increase bone mineral density (BMD) and decrease fracture risk in postmenopausal women with osteoporosis, but the need for long-term treatment is unclear, especially ...

Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008;168:826-831. Data from the Group Health Atrial ...

Please provide your email address to receive an email when new articles are posted on . Compared with other first-line osteoporosis treatments, alendronate therapy yielded an increased risk for ...

In this analysis, 3 bisphosphonates (alendronate, pamidronate, and zoledronic acid) and 1 RANK ligand inhibitor (denosumab) were evaluated for their effectiveness at preventing osteoclasts from ...

Romosozumab plus alendronate vs alendronate alone was associated with improved lumbar spine BMD among postmenopausal women with T2D and osteoporosis. Romosozumab followed by alendronate treatment ...

In re Fosamax (Alendronate Sodium), No. 11-5304, 08-08; U.S. District Court (DNJ); opinion by Pisano, U.S.D.J.; filed June 27, 2013. DDS No. 36-7-xxxx [17 pp.] Fosamax (Alendronate Sodium) is approved ...

Statin pills for patient with high cholesterol Decrease in bone mass is common in the first 6 to 12 months after kidney transplantation. Long-term use of alendronate, a bisphosphonate, may slow bone ...

Alendronate is a generic prescription drug that helps prevent and treat osteoporosis and other conditions. Alendronate’s cost may depend on your dosage, whether you have health insurance, and the ...

WHITEHOUSE STATION, N.J., June 25, 2010 - Merck & Co., Inc. today said it is challenging the decision returned by a New York jury in the retrial of a federal FOSAMAX case, Boles v. Merck. This case ...

In postmenopausal women with osteoporosis, prior fracture, and type 2 diabetes, 12 months of romosozumab significantly improved bone strength when combined with alendronate, compared with alendronate ...